COMMUNIQUÉS West-GlobeNewswire
-
PetMeds and Rural King Expand Access to Pet Healthcare Through New Online Pharmacy Platform
14/07/2026 -
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
14/07/2026 -
Verano Hosting Grand Opening Celebration of MÜV Bradfordville on Friday, July 17th, Elevating the Company’s Retail Footprint to 86 Florida Dispensaries and 163 Locations Nationwide
14/07/2026 -
Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
14/07/2026 -
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
14/07/2026 -
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
14/07/2026 -
Cannara Announces a Long-Term International Cannabis Supply Agreement with Curaleaf International Limited
14/07/2026 -
Smile Doctors Outpaces First-Half Growth Plan, Nears 600 Locations Nationwide
14/07/2026 -
ASPN 2026 to Feature Three Abstracts on SPRINT® PNS
14/07/2026 -
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026
14/07/2026 -
Cannara annonce la conclusion d’une entente internationale à long terme d’approvisionnement en cannabis avec Curaleaf International Limited
14/07/2026 -
PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
14/07/2026 -
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
14/07/2026 -
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
14/07/2026 -
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
14/07/2026 -
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
14/07/2026 -
XOMA Royalty Announces Closing of Its Acquisition by Ligand
14/07/2026 -
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
14/07/2026 -
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026
Pages